Guilin Sanjin Pharmaceutical Co., Ltd. and all members of the board guarantee that the information disclosed is true, accurate, and complete, without false records, misleading statements, or significant omissions.
Special Reminder: As of the date of this announcement, the actual guarantee balance of Guilin Sanjin Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") and its holding subsidiaries is RMB 263.71 million (including this guarantee), accounting for 8.76% of the Company's most recent audited net assets. The guaranteed party for this guarantee is the Company's wholly-owned subsidiary, Baifan Biotechnology (Shanghai) Co., Ltd. (hereinafter referred to as "Baifan"), which has a debt-to-asset ratio exceeding 70%. The Company and its holding subsidiaries have not provided guarantees for entities outside the consolidated financial statements, nor do they have overdue debts corresponding to guarantee balances, amounts involved in litigation, or guarantee amounts due to judgments against them. Investors are advised to pay close attention to guarantee risks.